Descovy

E409695

HIV medication antiretroviral medication combination drug pharmaceutical drug

Descovy is a prescription antiretroviral medication from Gilead Sciences used for the treatment and prevention (PrEP) of HIV-1 infection.

Try in SPARQL Jump to: Surface forms Disambiguation Statements Elicitation Referenced by

All labels observed (2)

Label	Occurrences
Descovy canonical	1
emtricitabine	1

How this entity was disambiguated

This entity first appeared as the object of triple T4050928 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.

NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07

Target entity: Descovy
Context triple: [Gilead Sciences, product, Descovy]

A. Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
B. Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
C. Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
D. Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
E. Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
F. None of above. chosen
G. Unsure - the case is ambiguous/there is not enough information to decide.

NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07

Target entity: Descovy
Target entity description: Descovy is a prescription antiretroviral medication from Gilead Sciences used for the treatment and prevention (PrEP) of HIV-1 infection.

A. Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
B. Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
C. Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
D. Denesuline
Denesuline are a First Nations people of the larger Dene cultural and linguistic group, traditionally inhabiting subarctic regions of northern Canada.
E. Novafora
Novafora was a semiconductor company known for acquiring Transmeta to expand its presence in low-power microprocessor and video processing technologies.
F. None of above. chosen

Statements (51)

Predicate	Object
instanceOf	HIV medication ⓘ antiretroviral medication ⓘ combination drug ⓘ pharmaceutical drug ⓘ
ATCCode	J05AR17 ⓘ
benefitComparedToTDFRegimens	less impact on bone mineral density ⓘ less impact on renal function ⓘ
blackBoxWarning	post-treatment acute exacerbation of hepatitis B ⓘ risk of drug resistance with use as monotherapy for HIV-1 ⓘ
commonAdverseEffect	diarrhea ⓘ fatigue ⓘ headache ⓘ nausea ⓘ
containsComponentBrand	emtricitabine ⓘ tenofovir alafenamide ⓘ
containsSubstance	emtricitabine 120 mg (in pediatric tablet strength) ⓘ emtricitabine 200 mg (in one tablet strength) ⓘ tenofovir alafenamide 15 mg (in pediatric tablet strength) ⓘ tenofovir alafenamide 25 mg (in one tablet strength) ⓘ
contraindication	severe renal impairment (per label thresholds) ⓘ
countryOfApproval	United States ⓘ linked to: United States of America
developer	Gilead Sciences ⓘ linked to: Gilead Sciences (board member)
dosageForm	film-coated tablet ⓘ
drugClass	nucleoside reverse transcriptase inhibitor ⓘ nucleotide reverse transcriptase inhibitor ⓘ
formulation	oral tablet ⓘ
hasActiveIngredient	emtricitabine ⓘ tenofovir alafenamide ⓘ
indication	PrEP for HIV-1 ⓘ pre-exposure prophylaxis of HIV-1 infection ⓘ treatment of HIV-1 infection ⓘ
indicationLimitation	not indicated for PrEP in individuals at risk from receptive vaginal sex (per U.S. label as of 2024) ⓘ
indicationPopulation	adolescents at risk of HIV-1 infection ⓘ adolescents with HIV-1 infection ⓘ adults at risk of HIV-1 infection ⓘ adults with HIV-1 infection ⓘ
legalStatus	prescription-only ⓘ
manufacturer	Gilead Sciences ⓘ linked to: Gilead Sciences (board member)
mechanismOfAction	inhibition of HIV-1 reverse transcriptase ⓘ termination of viral DNA chain elongation ⓘ
onceDaily	true ⓘ
pregnancyCategory	consult label and clinician for use in pregnancy ⓘ
regulatoryAgency	U.S. Food and Drug Administration ⓘ linked to: Food and Drug Administration
routeOfAdministration	oral ⓘ
therapeuticArea	HIV prevention ⓘ HIV treatment ⓘ infectious disease ⓘ
usedWith	other antiretroviral agents for HIV-1 treatment ⓘ
warning	risk of acute exacerbation of hepatitis B after discontinuation ⓘ risk of lactic acidosis ⓘ risk of severe hepatomegaly with steatosis ⓘ